Molly Henderson Sells 6,583 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 6,583 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total value of $43,381.97. Following the completion of the sale, the chief financial officer now directly owns 93,546 shares in the company, valued at approximately $616,468.14. This trade represents a 6.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Molly Henderson also recently made the following trade(s):

• On Thursday, December 19th, Molly Henderson sold 1,291 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $8.00, for a total value of $10,328.00.

Phathom Pharmaceuticals Stock Performance

NASDAQ:PHAT opened at $6.90 on Friday. The stock has a market cap of $471.80 million, a price-to-earnings ratio of -1.21 and a beta of 0.56. Phathom Pharmaceuticals, Inc. has a 1 year low of $6.07 and a 1 year high of $19.71. The business has a fifty day moving average of $8.00 and a 200-day moving average of $12.47.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its earnings results on Thursday, November 7th. The company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.57) by $0.25. The company had revenue of $16.35 million during the quarter, compared to the consensus estimate of $12.54 million. During the same quarter in the prior year, the company earned ($0.76) EPS. On average, equities research analysts predict that Phathom Pharmaceuticals, Inc. will post -4.74 EPS for the current year.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PHAT. State Street Corp boosted its stake in Phathom Pharmaceuticals by 17.5% during the 3rd quarter. State Street Corp now owns 922,788 shares of the company’s stock valued at $16,684,000 after purchasing an additional 137,539 shares in the last quarter. Eagle Asset Management Inc. lifted its holdings in shares of Phathom Pharmaceuticals by 25.9% in the third quarter. Eagle Asset Management Inc. now owns 455,196 shares of the company’s stock valued at $7,675,000 after buying an additional 93,733 shares during the period. FMR LLC boosted its stake in Phathom Pharmaceuticals by 49,000.7% during the third quarter. FMR LLC now owns 1,304,114 shares of the company’s stock valued at $23,578,000 after buying an additional 1,301,458 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Phathom Pharmaceuticals during the third quarter worth about $7,952,000. Finally, Jennison Associates LLC raised its position in Phathom Pharmaceuticals by 112.7% in the third quarter. Jennison Associates LLC now owns 5,866,389 shares of the company’s stock worth $106,064,000 after acquiring an additional 3,108,810 shares in the last quarter. Institutional investors own 99.01% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.